Amanta Healthcare Reports Q2FY27 IPO Proceeds Utilization and Capex Delays
Amanta Healthcare Ltd 路 Others (Uncategorized) 路 04 Nov 2026, 7:23 pm
Amanta Healthcare Reports Q2FY27 IPO Proceeds Utilization and Capex Delays CRISIL Ratings issued the Monitoring Agency Report for Amanta Healthcare for the quarter ended 30th Sep'26 regarding its Rs 12,600 lakh IPO proceeds. Total utilization reached Rs 10,082.69 lakh, leaving Rs 2,517.31 lakh unutilized, primarily deployed in bank fixed deposits. Net capex deployment across SteriPort and SVP manufacturing lines stood at Rs 7,495.43 lakh versus the original Rs 8,000 lakh FY26 estimate, reflecting project implementation delays due to supplier terms finalization and delayed work completion. No deviation was reported in issue objects.
Original exchange filing (PDF)
More announcements from Amanta Healthcare Ltd
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Vishal Ashokkumar Patel 路 18 Nov 2026
- submission of Disclosures under Regulation 7(2) of The SEBI (Prohibition of Insider Trading) Regulations, 2015 - off-market transfer of equity shares 路 18 Nov 2026
- Company Response On The Spurt In Volume Of Security Across Exchanges 路 14 Nov 2026
- The Exchange has sought clarification from Amanta Healthcare Ltd on November 13, 2026, with reference to Movement in Volume. <BR><BR>The reply is awaited. 路 13 Nov 2026
- Transcript of Post Results Conference call held on November 4, 2026 路 09 Nov 2026
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jitendrakumar Jashbhai Patel 路 09 Nov 2026
- submission of Disclosure under Regulation 7(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015 (the "Insider Trading Regulations") 路 07 Nov 2026
- submission of Audio Recording of Post Results Conference Call held on November 4, 2026 路 04 Nov 2026
